Hypophosphatemia in juvenile patients with systemic lupus erythematosus

Pediatrics International

Volumn 45, Issue 1, 2003, Pages 23-30

  Fujiwara, Ikuma ^a   Ogawa, Eishin ^a   Kondo, Yoshiaki ^a   Ohura, Toshihiro ^a   Iinuma, Kazuie ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cytokine; Hypophosphatemia; Phosphate; Systemic lupus erythematosus; Tubular reabsorption

Indexed keywords

DNA ANTIBODY; INTERLEUKIN 6; PHOSPHATE; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ARTICLE; CLINICAL ARTICLE; COMPLEMENT BLOOD LEVEL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE; FEMALE; HUMAN; HYPOPHOSPHATEMIA; KIDNEY TUBULE ABSORPTION; LUPUS ERYTHEMATOSUS NEPHRITIS; PATHOGENESIS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SCHOOL CHILD; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE;

ADOLESCENT; CHILD; FEMALE; HUMANS; HYPOPHOSPHATEMIA; INTERLEUKIN-6; LUPUS ERYTHEMATOSUS, SYSTEMIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037322836     PISSN: 13288067     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-200X.2003.01665.x     Document Type: Article

References (28)

1. Kotzin BL, O'Dell JR. Systemic lupus erythematosus. In: Frank MM, Austen KF, Claman HN, Unanue ER (eds). Samter's Immunologic Diseases. 5th edn. Lippincott-Raven, Philadelphia, 1995; 667-97.
2. Arkachaisri T, Lehman TJ. Systemic lupus erythematosus and related disorders of childhood. Curr. Opin. Reumatol. 1999; 11: 384-92.
3. Drezner MK. PHEX gene and hypophosphatemia. Kidney Int. 2000; 57: 9-18.
4. The ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat. Genet. 2000; 26: 345-8.
5. Yamamoto T, Ozono K, Kasayama S et al. Increased IL-6-production by cells isolated from the fibrous bone dysplasia tissues in patients with McCune-Albright syndrome. J. Clin. Invest. 1996; 98: 30-35.
6. White KE, Jonsson KB, Carn G et al. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J. Clin. Endocrinol. Metab. 2001; 86: 497-500.
7. Subramanian R, Khardori R. Severe hypophosphatemia. Pathophysiologic implications, clinical presentations, and treatment. Medicine (Baltimore). 2000; 79: 1-8.
8. Barak V, Schwartz A, Kalickman I, Nisman B, Gurman G, Shoenfeld Y. Prevalence of hypophosphatemia in sepsis and infection: the role of cytokines. Am. J. Med. 1998; 104: 40-47.
9. Dean GS, Tyrrell-Price J, Crawley E, Isenberg DA. Cytokines and systemic lupus erythematosus. Ann. Rheum. Dis. 2000; 59: 243-51.
10. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. The Committee on Prognosis Studies in SLE. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum. 1992; 35: 630-40.
11. Brunner HI, Feldman BM, Bombardier C, Silverman ED. Sensitivity of the Systemic Lupus Erythematosus Disease Activity Index, British Isles Lupus Assessment Group Index, and Systemic Lupus Activity Measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus. Arthritis Rheum. 1999; 42: 1354-60.
12. Walton RJ, Bijvoet OL. Nomogram for derivation of renal threshold phosphate concentration. Lancet 1975; 2: 309-10.
13. Pisetsky DS. Anti-DNA antibodies in systemic lupus erythematosus. Rheum. Dis. Clin. North. Am. 1992; 18: 437-54.
14. Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J. Immunol. 1991; 147: 117-23.
15. Richards HB, Satoh M, Shaw M, Libert C, Poli V, Reeves WH. Interleukin-6 dependence of anti-DNA antibody production: Evidence for two pathways of autoantibody formation in pristane-induced lupus. J. Exp. Med. 1998; 188: 985-90.
16. Cross JT, Benton HP. The roles of interleukin-6 and interleukin-10 in B cell hyperactivity in systemic lupus erythematosus. Inflamm. Res. 1999; 48: 255-61.
17. Davas EM, Tsirogianni A, Kappou I, Karamitsos D, Economidou I, Dantis PC. Serum IL-6, TNFα, p55 srTNFα, p75srTNFα, srIL-2α levels and disease activity in systemic lupus erythematosus. Clin. Rheumatol. 1999; 18: 17-22.
18. Hirohata S, Miyamoto T. Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum. 1990; 33: 644-9.
19. Herrera-Esparza R, Barbosa-Cisneros O, Villalobos-Hurtado R, Avalos-Diaz E. Renal expression of IL-6 and TNFα genes in lupus nephritis. Lupus 1998; 7: 154-8.
20. del Giglio A, Zukiwski AA, Ali MK, Mavligit GM. Severe, symptomatic, dose-limiting hypophosphatemia induced by hepatic arterial infusion of recombinant tumor necrosis factor in patients with liver metastases. Cancer 1991; 67: 2459-61.
21. Furukawa S, Matsubara T, Yone K, Hirano Y, Okumura K, Yabuta K. Kawasaki disease differs from anaphylactoid purpura and measles with regard to tumour necrosis factor-α and interleukin-6 in serum. Eur. J. Pediatr. 1992; 151: 44-7.
22. Yoshizaki K, Matsuda T, Nishimoto N et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 1989; 74: 1360-67.
23. Tzoufi M, Siamopoulou-Mavridou A, Challa A, Lapatsanis PD. Changes of mineral metabolism in juvenile chronic arthritis. Acta Paediatr. Suppl. 1994; 394: 552-7.
24. Turner ST, Kiebzak GM, Dousa TP. Mechanism of glucocorticoid effect on renal transport of phosphate. Am. J. Physiol. 1982; 243: C227-36.
25. Park S-H, Taub M, Han H-J. Regulation of phosphate uptake in primary cultured rabbit renal proximal tubule cells by glucocorticoids: Evidence for nongenomic as well as genomic mechanisms. Endocrinology 2001; 142: 710-20.
26. Azuma Y, Kaji K, Katogi R, Takeshita S, Kudo A. Tumor necrosis factor-α induces differentiation of and bone resorption by osteoclasts. J. Biol. Chem. 2000; 275: 4858-64.
27. Manolagas SC. The role of IL-6 type cytokines and their receptors in bone. Ann. N Y Acad. Sci. 1998; 840: 194-204.
28. Ekdahl KN, Ronnblom L, Sturfelt G, Nilsson B. Increased phosphate content in complement component C3, fibrinogen, vitronectin, and other plasma proteins in systemic lupus erythematosus: covariation with platelet activation and possible association with thrombosis. Arthritis Rheum. 1997; 40: 2178-86.